Beam Therapeutics Inc (BEAM) — Cash Flow Reinvestment Rate

Latest as of December 2023: 0.75x

Beam Therapeutics Inc (BEAM) has a Cash Flow Reinvestment Rate of 0.75x as of December 2023, reinvesting $101.69 Million (capex $3.59 Million plus investments $98.10 Million) from operating cash flow of $135.07 Million. Explore Beam Therapeutics Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.75x
(Capex + Investments) / Operating CF

Total Reinvested

$101.69 Million
Capex + Investments

Operating Cash Flow

$135.07 Million
USD

Capital Expenditures

$3.59 Million
USD

Beam Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Beam Therapeutics Inc across 1 annual periods. Also explore how large is Beam Therapeutics Inc's balance sheet for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Beam Therapeutics Inc (2022–2022)

Year-by-year capital reinvestment analysis for Beam Therapeutics Inc. For live market cap and broader valuation context, see BEAM company net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 22.65x $510.29 Million $22.53 Million $48.95 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow